<DOC>
	<DOC>NCT02683109</DOC>
	<brief_summary>This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled study. Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of either FDC of tiotropium + olodaterol (5/5 µg) plus placebo or the free combination of tiotropium 5 µg and olodaterol 5 µg; all administered via the Respimat® inhaler. The purpose is to show non-inferiority between the FDC and the free combination of tiotropium and olodaterol in patients with COPD.</brief_summary>
	<brief_title>Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Male or female patients. Patients 40 years of age or older. Patients with a smoking history &gt; 10 pack years. Diagnostic of COPD with Postbronchodilator FEV1 &gt;= 30% and &lt;80% of predicted normal and Postbronchodilator FEV1/FVC &lt;70% at screening. Symptomatic patients with CAT score &gt;= 10 at screening. Further inclusion criteria apply. Exclusion criteria: COPD exacerbation or symptoms of lower respiratory tract infection within 6 weeks prior to screening. Patients with a current diagnosis of asthma. Further exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>